Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06072001
NCT06072001RecruitingPhase 3

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Apurano Pharmaceuticals GmbH1 site in 1 country558 target enrollmentStarted: November 2, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
558
Locations
1
Primary Endpoint
Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to central neuropathy of any genesis. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to central neuropathy of any genesis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Signed and dated informed consent form
  • •Patients with chronic pain due to central neuropathy of any genesis since at least 3 months
  • •Female and male patients (> 18 years)
  • •Patients with more than 1 year life expectancy
  • •Patients with optimized sCPT on study entry as defined in section 3.1.1 and section 3.1.3 of the study protocol
  • •Willingness of study patients of both sexes to use reliable contraception during study participation and for three months after taking the last study medication
  • •Good command of German language, in order to understand questionnaires in German
  • •Current moderate to severe pain with pain intensity > 5 on Numeric Rating Scale (NRS, 0 - 10) and thus an existing need for further pain therapy
  • •Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with 45 or less score points

Exclusion Criteria

  • •Medical history of hypersensitivity or intolerance to the investigational product or its ingredients or to ingredients of similar chemical structure
  • •Known intolerance to cannabinoids or cannabis products.
  • •Participation in another clinical trial within the last four weeks prior to inclusion.
  • •Pregnant or nursing women (as excluded by pregnancy testing at visit 1).
  • •Other medical conditions that do not allow the trial subject to appraise the nature, scope, and potential consequences of the clinical trial
  • •Indications that the trial subject is unlikely to comply with the study protocol (e.g., unwillingness to cooperate)
  • •Known use of medicinal cannabis products within the last 8 weeks
  • •Active malignant tumor disease, tumor pain, or other dominant severe pain other than that of the study indication
  • •Known history of severe liver or kidney diseases
  • •Known history of severe cardiovascular disease
  • •Known history of or acute mental illness such as severe depression, psychosis, bipolar disorder, mania, anxiety, or obsessive-compulsive disorder
  • •Known history of addictive disease (e.g., alcohol, medication, drug addiction)
  • •Answered during Screening less than 12 times of 18 the pain intensity (NRS) inquiry
  • •Laboratory liver values: Alanine aminotransferase (ALT, GPT) > 3 x ULN (Upper Limit of Normal range), Aspartate aminotransferase (AST, GOT) > 3 x ULN, Alkaline phosphatase (AP) > 2.5 x ULN, and for bilirubin > 1.5 x ULN
  • •Laboratory renal value: Serum creatinine > 1.5 ULN

Arms & Interventions

Treatment group

Experimental

Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention: Adezunap (AP707) (Drug)

Control group

Experimental

Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)

Time Frame: Once daily in week 4 and 14

Secondary Outcomes

  • Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14, 26, and 52(Week 1, 14, 26 and 52)
  • Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 26 (end of second treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)(Once daily in week 4 and 26)
  • Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14, 26, and 52(Week 1, 14, 26 and 52)
  • Change of Patient Global Impression of Change (PGIC) from start to week 14, 26, and 52(Week 14, 26 and 52)
  • Area under NRS-curve until treatment week 5, 11, 14, 18, 22, 26, 30, 34, 39, 43, 47, 52(Week 5, 12, 18, 22, 26, 30, 34, 39, 43, 47 and 52)
  • Responder analysis for endpoints 1), 2), 3) and 4) for treatment week 14, 26 and 52(Week 14, 26 and 52)
  • Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 52 (end of third treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)(Once daily in week 4 and 52)
  • Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14, treatment week 26 and treatment week 52 in comparison of study arm 1 (verum) and study arm 2 (placebo)(Once in week 1, 14, 26 and 52)
  • Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5, 11, 18, 22, 30, 34, 43, 47 in comparison of study arm 1 (verum) and study arm 2 (placebo)(Several times weekly in week 4, 5, 11, 18, 22, 30, 34, 43 and 47)
  • Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14, 26, and 52(Week 1, 14, 26 and 52)
  • Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52(Week 5, 11, 14, 18, 22, 26, 30, 34, 43, 47 and 52)
  • Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14(Week 14)
  • Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14, 26, and 52(Week 1, 14, 26 and 52)
  • Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14, 26, and 52(Week 1, 14, 26 and 52)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 3
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyPainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeDiabetesDiabetic NeuropathiesDiabetic PolyneuropathyPeripheral NeuralgiaPeripheral Neuropathy With Type 2 DiabetisPeripheral Neuropathy
NCT06071975Apurano Pharmaceuticals GmbH558
Recruiting
Phase 3
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back PainPainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeBack PainLower Back PainLower Back Pain Chronic
NCT06071962Apurano Pharmaceuticals GmbH558
Recruiting
Phase 3
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyPainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeNeuropathic PainPeripheral NeuralgiaPeripheral Nerve InjuryPost Operative PainPost-Traumatic NeuralgiaPlexopathyPeripheral Neuropathy
NCT06071988Apurano Pharmaceuticals GmbH558
Recruiting
Phase 3
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any GenesisPainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeNeuropathic PainCentral Neuropathic PainParaplegiaPhantom Limb Syndrome With PainPhantom PainTraumatic Brain InjuryMultiple SclerosisStroke
NCT06071949Apurano Pharmaceuticals GmbH558
Recruiting
Phase 3
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyPainPain SyndromePain, ChronicChronic PainChronic Pain SyndromeNeuropathic PainPeripheral NeuralgiaPeripheral Nerve InjuryPost Operative PainPost-Traumatic NeuralgiaPlexopathyPeripheral Neuropathy
NCT06071936Apurano Pharmaceuticals GmbH558
Long Term Efficacy and Tolerability of... | Clinical Trial